9 METERS BIOPHARMA, INC. (NMTR) is a publicly traded company in the Unknown sector. Across all available filings, 11 corporate insiders have executed 59 transactions totaling $22.5M, demonstrating a bearish sentiment with -$19.4M in net insider flow. The most recent transaction on Apr 21, 2023 involved a sale of 9,100 shares valued at $11.0K.
No significant insider buying has been recorded for NMTR in the recent period.
No significant insider selling has been recorded for NMTR in the recent period.
Based on recent SEC filings, insider sentiment for NMTR is bearish with an Insider Alignment Score of 7/100 and a net flow of -$19.4M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at 9 METERS BIOPHARMA, INC. (NMTR) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 11 insiders are actively trading NMTR stock, having executed 59 transactions in the past 90 days. The most active insider is Israel Biofund Gp Limited Partnership Orbimed (Executive), who has made 8 transactions totaling $21.0M.
Get notified when executives and directors at NMTR file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Apr 21, 2023 | Sensenig Bethany | Executive | Sale | 9,100 | $1.21 | $11.0K | |
| Mar 29, 2023 | Ventimiglia Samantha | Executive | Award | 7,885 | $N/A | $0 | |
| Mar 29, 2023 | T. Constantino Michael | Executive | Award | 7,885 | $N/A | $0 | |
| Mar 29, 2023 | K. Johnson Lorin | Executive | Award | 7,885 | $N/A | $0 | |
| Mar 29, 2023 | Michael Rice Yehuda | Executive | Award | 7,885 | $N/A | $0 | |
| Mar 29, 2023 | A. Sirgo Mark | Executive | Award | 7,885 | $N/A | $0 | |
| Mar 27, 2023 | Temperato John | Executive | Award | 68,815 | $N/A | $0 | |
| Mar 27, 2023 | Sensenig Bethany | Executive | Award | 50,177 | $N/A | $0 | |
| Jul 6, 2022 | Temperato John | Executive | Purchase | 125,000 | $0.23 | $28.8K | |
| Jul 1, 2022 | A. Sirgo Mark | Executive | Purchase | 175,000 | $0.25 | $43.8K | |
| Jul 1, 2022 | A. Sirgo Mark | Executive | Award | 175,000 | $0.25 | $43.8K | |
| May 23, 2022 | T. Constantino Michael | Executive | Purchase | 16,000 | $0.48 | $7.7K | |
| May 18, 2022 | A. Sirgo Mark | Executive | Purchase | 106,383 | $0.47 | $50.0K | |
| May 18, 2022 | Temperato John | Executive | Purchase | 50,000 | $0.45 | $22.5K | |
| Mar 3, 2022 | Temperato John | Executive | Purchase | 100,000 | $0.56 | $56.0K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 4 | $20.9M | 92.7% |
Purchase(P) | 31 | $1.6M | 7.0% |
Award(A) | 11 | $43.8K | 0.2% |
Exercise (Options)(X) | 2 | $20.8K | 0.1% |
Other(J) | 4 | $0 | 0.0% |
Conversion(C) | 7 | $0 | 0.0% |
Insider selling pressure at 9 METERS BIOPHARMA, INC. has increased, with 11 insiders executing 59 transactions across all time. Total sales of $20.9M significantly outpace purchases of $1.6M, resulting in a net outflow of $19.4M. This selling activity appears largely discretionary, which may warrant closer attention from investors.